Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
Olema Pharmaceuticals Inc.
OLMAUS
$
0.02
0.26%
After Hours
$
7.84
After Hours Volume:
3.51K
| Close | Chg | Chg % |
|---|---|---|
| $7.82 | 1.27 | 19.39% |
Volume: 773.65K
65 Day Avg: 198.36K
6.63
Day Range
8.05
2.19
52 Week Range
8.05
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
OLMA Overview
Key Data
- Open $6.63
- Day Range 6.63 - 8.05
- 52 Week Range 2.19 - 8.05
- Market Cap $266.99M
- Shares Outstanding 40.76M
- Public Float 34.64M
- Beta 1.68
- Rev. per Employee N/A
- P/E Ratio N/A
- EPS -$2.74
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 1.03M 05/31/23
- % of Float Shorted 2.96%
- Average Volume 198.36K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 8
Full Ratings
Recent News
Activist Investing GCP Applied Tech, Cricut See Action From Activist Investors
Olema Pharmaceuticals started at buy with $60 stock price target at Canaccord Genuity
Olema Pharmaceuticals started at overweight with $52 stock price target at J.P. Morgan
Recap: Olema Pharmaceuticals Q1 Earnings
on Benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
on Benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
on Benzinga.com
H.C. Wainwright Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Olema Pharmaceuticals (OLMA - Research Report) today and set a price target of $12.00. The company's shares closed yesterday at $2.62.Bodnar covers the Health...
on TipRanks.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
on Benzinga.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (A), Vapotherm (VAPO) and Olema Pharmaceuticals (OLMA)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilent (A – Research Report), Vapotherm (VAPO – Research Report) and Olema Pharmaceuticals (OLMA – Research Report). Agilent (A) Jefferies ...
on TipRanks.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
on Benzinga.com
Olema Pharmaceuticals (OLMA) Receives a Buy from H.C. Wainwright
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals (OLMA - Research Report), with a price target of $12.00. The company's shares closed yesterday at $3.13.Accordi...
on TipRanks.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
on Benzinga.com
Olema Oncology to host conference call
Conference call to review data presented at the 34th EORTC-NCI-AACR Symposium on October 26 at 8 am. Webcast LinkPublished first on TheFlySee today’s best-performing stocks on TipRanks >>Read More on OLMA:Olema Oncology An...
on TipRanks.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
on InvestorPlace.com
H.C. Wainwright Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Olema Pharmaceuticals (OLMA - Research Report), with a price target of $12.00. The company's shares closed yesterday at $5.61.Accordi...
on TipRanks.com
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
on Benzinga.com
Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug
The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.
on Zacks.com
Olema Pharmaceuticals Inc.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. It also focuses on developing therapies for the treatment of breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.